skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Disease-modifying therapies in relapsing–remitting multiple sclerosis

Evidence to Practice

(7409) Views  (844) Full article downloads

Authors: Fabricio González-Andrade, José Luis Alcaraz-Alvarez

Published Date July 2010 Volume 2010:6(1) Pages 365 - 373
DOI: http://dx.doi.org/10.2147/NDT.S11079

Fabricio González-Andrade1, José Luis Alcaraz-Alvarez2

1Department of Medicine, Metropolitan Hospital, Quito, Ecuador; 2School of Medicine, University of Mayab, Merida, Mexico

Clinical question: What is the best current disease-modifying therapy for relapsing–remitting multiple sclerosis?

Results: The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-frequency subcutaneous interferon-β1a 44 μg three times per week.

Implementation: The pitfalls in treatment of MS can be avoided by remembering the following points:

• The most effective therapy to prevent or delay the appearance of permanent neurological disability with the fewest side effects should be chosen, and treatment should not be delayed.

• Adherence to treatment should be monitored closely, and needs comprehensive patient information and education to establish long-term adherence, which is a critical determinant of long-term outcome.

• The correct approach to the disease includes disease management, symptom management, and patient management. A combination of tools is necessary to ease the various symptoms, which fall into three broad categories, i.e. rehabilitation, pharmacological, and procedural.

• It is important to understand that no treatment modality should be used alone, unless it is in itself sufficient to remedy the particular symptom/problem.

Keywords: relapsing–remitting multiple sclerosis, interferon, disease-modifying therapy, relapse prevention






 

Other articles by Dr Jorge Fabricio Gonzalez-Andrade



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease